H. Res. 1167 is a simple, nonbinding House resolution that designates April 2026 as “Parkinson’s Awareness Month” and lists the House’s support for the month, its goals, and continued research into Parkinson’s disease.
The resolution cites incidence and burden statistics, recognizes clinical‑trial participants and caregivers, and commends organizations and volunteers working on Parkinson’s issues.
The measure matters because it frames Parkinson’s disease as a growing public‑health concern and creates a federal-level recognition event that advocacy groups, agencies, and health systems can cite in outreach and fundraising. It does not appropriate money or create regulatory obligations; its practical effect is reputational and programmatic rather than fiscal or legal.
At a Glance
What It Does
The resolution designates April 2026 as Parkinson’s Awareness Month, enumerates five expressions of support (designation, support for goals, continued research support, recognition of clinical trial participants, and commendation of stakeholders), and repeats several epidemiological findings about incidence, projected prevalence, and economic burden. It does not establish new authorities, programs, or appropriations.
Who It Affects
Directly affected stakeholders include people living with Parkinson’s, care partners, advocacy and research organizations, clinicians and investigators running trials, and federal public‑health agencies that may use the designation for outreach. Private-sector actors—hospitals, foundations, and employers—may also adopt the designation in communications and programming.
Why It Matters
The resolution creates a national moment to coordinate awareness campaigns, fundraising, and trial recruitment and provides a congressional imprimatur that advocacy groups can leverage with donors and agencies. Because it is nonbinding, its real-world impact will depend on who uses the designation and whether it catalyzes follow‑on funding or policy actions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution is a concise expression of support rather than a law. It opens with a set of factual findings about Parkinson’s disease—prevalence, annual diagnoses, projected growth to 1.7 million affected individuals by 2045, and an estimated future economic cost—then moves into five short “resolved” clauses that implement the congressional recognition.
Those clauses formally designate April 2026 as Parkinson’s Awareness Month, endorse the month’s goals, affirm continued support for research, recognize people who join clinical trials, and commend organizations and volunteers.
Because this is a House resolution (not a statute), it does not create new duties for federal agencies, authorize appropriations, or change Medicare, Medicaid, or other programs. The practical effect is to provide a named observance that public and private actors can reference.
Federal agencies such as the CDC or NIH could use the designation to time communications, guidance, or grant solicitations, but they would need existing budgets and authorities to do so.For advocacy groups and researchers, the designation functions as a tool: it strengthens arguments for donors, can be used to coordinate nationwide events, and may increase public attention that supports trial recruitment. For clinicians and trial sites, a public awareness month often correlates with higher inquiries and enrollment interest, though it does not remove underlying recruitment barriers like trial design, eligibility, or logistics.The resolution also puts a spotlight on caregivers, noting substantial economic impacts on care partners.
That recognition can translate into messaging around caregiver supports and employer accommodations, but such changes would require separate legislative or administrative action. Finally, the text praises volunteers and organizations—an explicit cue that Congress views the public and private sectors as the primary actors to operationalize awareness activities rather than committing federal resources directly.
The Five Things You Need to Know
The resolution cites that Parkinson’s disease affects over 1,000,000 people in the U.S. and that nearly 90,000 people receive a diagnosis each year.
It describes Parkinson’s as the fastest‑growing and second most common neurodegenerative disease and projects 1.7 million U.S. cases by 2045 with an estimated $112.4 billion cumulative cost.
The House ‘resolves’ five items: designate April 2026 as Parkinson’s Awareness Month; support the month’s goals; continue to support research; recognize clinical‑trial participants; and commend organizations and volunteers.
H. Res. 1167 is nonbinding and contains no appropriation language or regulatory mandates—its effect is symbolic and communicative, not fiscal.
The resolution was introduced by Rep. Wesley Bell, referred to the House Committee on Energy and Commerce, and contains explicit caregiver burden data (noting $8.3 billion in lost earnings for care partners in 2024).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings on prevalence, burden, and causes
The preamble assembles epidemiological and economic data: current prevalence (over 1 million), annual diagnoses (nearly 90,000), characterization as a rapidly growing neurodegenerative disease, anticipated prevalence by 2045 (1.7 million), projected aggregate cost ($112.4 billion), a list of common symptoms, and a caregiver burden estimate ($8.3 billion in lost earnings for care partners in 2024). These findings frame the public‑health rationale for heightened awareness and provide source language that advocates and agencies can quote when justifying outreach or grant priorities.
Designation of Parkinson’s Awareness Month
This clause formally designates April 2026 as Parkinson’s Awareness Month. In legislative practice, that kind of designation signals congressional interest and provides an official observance to reference in proclamations, press releases, and coordinated campaigns. It does not create programmatic obligations or funding lines—its power is to confer visibility.
Support for goals and research
The resolution declares congressional support for the goals and ideals of the awareness month and states that Congress ‘continues to support research’ toward better treatments and a cure. Practically, this is an endorsement rather than a directive: it expresses policy preference and may be cited by researchers and advocates when seeking appropriations or private funding, but it does not change existing grant authorities or budgets.
Recognition of clinical‑trial participants
Congress recognizes individuals who participate in clinical trials as playing a vital role in advancing knowledge. That recognition can be leveraged in trial recruitment messaging and public relations—Congress signals appreciation—but the clause does not alter consent, compensation, or regulatory frameworks that govern human subjects research.
Commendation of stakeholders
The final clause commends organizations, volunteers, researchers, and individuals working to improve quality of life. This is a public endorsement that can amplify partner organizations’ fundraising and outreach efforts and create an implied expectation that civic and private actors will take the lead in programming tied to the month.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with Parkinson’s — receive national visibility that advocates can use to drive awareness, attract volunteers, and support community programming focused on symptoms, care, and dignity.
- Care partners and family caregivers — gain congressional recognition of economic and emotional burdens, which advocacy groups can cite when lobbying for caregiver supports and employer accommodations.
- Advocacy and research organizations — obtain a federally recognized observance to anchor fundraising drives, public events, and media campaigns, boosting outreach and potentially increasing donations and volunteer engagement.
- Clinical researchers and trial sites — may see increased public interest and improved recruitment windows tied to awareness activities, helping address enrollment challenges for some studies.
- Federal public‑health agencies (CDC, NIH) — gain a clear, time‑bound occasion to concentrate communications and education efforts using existing authorities and budgets.
Who Bears the Cost
- Nonprofit advocacy groups and local organizers — expected to shoulder planning and event costs if they mobilize activities around the month, absorbing marketing, staffing, and venue expenses.
- Federal agencies — could incur opportunity costs if they redirect communication staff/time to Parkinson’s awareness without additional appropriations, given the resolution creates expectations but no funding.
- Clinical trial operations and health systems — may face short-term surges in inquiries that increase administrative burden for screening and triage without providing extra resources.
- Policymakers and program administrators — encounter pressure to convert symbolic recognition into concrete policy or funding requests, which can strain limited budgets or legislative agendas.
- Donor community and foundations — may face increased solicitation volume and greater competition among health causes during the awareness month, potentially diluting small donors’ impact.
Key Issues
The Core Tension
The central tension is between symbolic recognition and substantive change: the resolution elevates Parkinson’s disease on the national agenda and creates expectations for action, yet it stops short of providing money, new authorities, or concrete policy solutions—leaving governments and organizations to decide whether and how to translate recognition into resources.
The resolution’s chief limitation is its symbolic nature. By designating an awareness month and expressing support for research, it signals congressional priorities without changing funding levels, regulatory authority, or service delivery.
That creates a common legislative dilemma: visibility increases expectations from constituents and advocacy groups, but Congress has not provided the fiscal instruments within this bill to meet those expectations. Implementation therefore depends on agencies and private actors taking voluntary steps.
The text also bundles epidemiological and economic statistics that advocates will use to press for action, but those figures raise questions about methodology and policy prescriptions that the resolution does not address. For example, recognizing the economic burden on care partners highlights a need for caregiver supports, yet the resolution offers no mechanism to expand respite care, tax relief, or workplace protections.
The clause recognizing clinical‑trial participants praises their role but does not confront systemic recruitment barriers—eligibility criteria, geographic access, or trial costs—which remain unresolved and require separate policy or funding steps.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.